Abstract
CONCLUSIONS: These data suggest that TXA decreases the time to initial clot formation and increases the rate of clot propagation indicating its procoagulant effects beyond fibrinolysis, which are relevant to both potential benefit as well as safety. Thus, it is imperative to confirm a diagnosis of pathologic fibrinolysis prior to treatment with TXA to avoid exposure of a patient to a potentially thrombogenic drug.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
